Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-10T10:12:12.745Z Has data issue: false hasContentIssue false
  • English
  • Français

Clozapine-treated NMS

Published online by Cambridge University Press:  03 January 2018

M. F. Burrell ,
C. Fewster ,
E. Szabadi  and
M. Cashman
M. F. Burrell
Affiliation:
Whittingham Hospital Whittingham, Preston Lancashire PR3 2JH
C. Fewster
Affiliation:
Whittingham Hospital Whittingham, Preston Lancashire PR3 2JH
E. Szabadi
Affiliation:
Withington Hospital West Didsbury Manchester
M. Cashman
Affiliation:
Victoria Hospital Blackpool, Lancashire
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Information
The British Journal of Psychiatry , Volume 158 , Issue 4 , April 1991 , pp. 577
Copyright
Copyright © Royal College of Psychiatrists, 1991 

References

Coward, D. M., Imperato, A., Urwyler, S., et al (1989) Biochemical and behavioural properties of clozapine. Psychopharmacology, 99, S6–S12.Google ScholarPubMed
Kane, J., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment of resistant schizophrenic. Archives of General Psychiatry, 45, 789–796.Google Scholar
Susman, V. L. & Addonizio, G. (1988) Recurrence of neuroleptic malignant syndrome. Journal of Nervous and Mental Disease, 176, 234–241.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.